Giant cell arteritis in sight - Imaging techniques in the ZGT GET cohort

Giant cell arteritis in sight - Imaging techniques in the ZGT GET cohort - Giant cell arteritis in sight

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49395

Enrollment

Registered

2020-03-06

Start date

2020-07-17

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giant cell arteritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with a suspicion of GCA (based on the suspicion of the treating rheumatologist or the referring general practitioner)

Exclusion criteria

Exclusion criteria: - Contra-indications, as used in regular care, for the imaging techniques used (FDG-PET/CT of MRI/MRA) - Legally incapable

Design outcomes

Primary

Measure	Time frame
The diagnosis after 6 months. This will be used to calculate the sensitivity, specificity and AUC to evaluate the validity of the three imaging techniques. These values can then be compared for the three imaging techniques	—

Secondary

Measure	Time frame
The diagnoses after 6 months follow-up This will be used to calculate the sensitivity, specificity and AUC to evaluate the validity of the temporal artery biopsy. This can then also be compared to these values from the three imaging techniques	—

Countries

Netherlands

Outcome results